Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25272218 | 0.92 | KIT (0.45) | KITACACBCYP11B2GPR119NAMPT | |
| SCHEMBL25226496 | 0.89 | KIT (0.43) | KITACACBCYP11B2GPR119NAMPT | |
| SCHEMBL25270429 | 0.87 | KIT (0.45) | KITACACBCYP11B2GPR119NAMPT | |
| SCHEMBL25276952 | 0.84 | KIT (0.42) | KITACACBCYP11B2GPR119NAMPT | |
| SCHEMBL30456119 | 0.81 | KIT (0.49) | KITCYP11B2GPR119NAMPTSCD5 | |
| SCHEMBL31578997 | 0.78 | KIT (0.42) | KITACACBCYP11B2GPR119SCD5 | |
| SCHEMBL31578938 | 0.77 | CYP11B2 (0.48) | ACACBCYP11B2NAMPTSCD5HDAC1 | |
| SCHEMBL31027446 | 0.76 | NAMPT (0.41) | ACACBGPR119NAMPT | |
| SCHEMBL34467574 | 0.76 | ACACB (0.44) | KITACACBCYP11B2GPR119NAMPT | |
| SCHEMBL25246869 | 0.76 | ACACB (0.44) | KITACACBCYP11B2GPR119NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | KIT 1067/4885ACACB 1663/4885CYP11B2 1867/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | KIT 1067/4885ACACB 1663/4885CYP11B2 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.